Trade

with

AVANIR Pharmaceuticals
(NASDAQ: AVNR)
AdChoices
11.90
+0.24
+2.06%
After Hours :
11.90
0.00
0.00%

Open

11.80

Previous Close

11.66

Volume (Avg)

3.03M (5.43M)

Day's Range

11.71-12.10

52Wk Range

2.62-13.09

Market Cap.

2.00B

Dividend Rate ( Yield )

-

Beta

0.87

Shares Outstanding

171.83M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 75.37M

    • Net Income

    • -75.48M

    • Market Cap.

    • 2.00B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -69.03

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.87

    • Forward P/E

    • -

    • Price/Sales

    • 17.76

    • Price/Book Value

    • 30.67

    • Price/Cash flow

    • -25.51

      • EBITDA

      • -70.55M

      • Return on Capital %

      • -74.30

      • Return on Equity %

      • -161.31

      • Return on Assets %

      • -74.30

      • Book Value/Share

      • 0.39

      • Shares Outstanding

      • 171.83M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 8.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -0.02

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 44.90

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 61.04

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 94.64

            • 64.72

            • Pre-Tax Margin

            • -69.02

            • 13.77

            • Net Profit Margin

            • -69.03

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 95.30

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -454.20

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -454.20

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.19

              • 0.33

              • Current Ratio

              • 3.06

              • 1.52

              • Quick Ratio

              • 2.95

              • 0.87

              • Interest Coverage

              • -18.83

              • 6.77

              • Leverage Ratio

              • 1.78

              • 1.91

              • Book Value/Share

              • 0.39

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -25.51

                • 65.36

                • P/E Ratio 5-Year High

                • -28.30

                • 237.47

                • P/E Ratio 5-Year Low

                • -2.83

                • 19.71

                • Price/Sales Ratio

                • 17.61

                • 3.63

                • Price/Book Value

                • 30.40

                • 3.39

                • Price/Cash Flow Ratio

                • -25.51

                • 21.83

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -161.31

                    (-141.30)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -74.30

                    (-75.60)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -95.70

                    (-107.40)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • 8.67

                  • 1.80

                  • Asset Turnover

                  • 1.08

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -71.43M
                  Operating Margin
                  -94.77
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -25.51
                  Ownership

                  Institutional Ownership

                  74.08%

                  Top 10 Institutions

                  56.81%

                  Mutual Fund Ownership

                  41.19%

                  Float

                  85.78%

                  5% / Insider Ownership

                  3.64%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    9,758,113

                  • 0.00

                  • 5.68

                  • T. Rowe Price Health Sciences Fund

                  •  

                    8,804,970

                  • -0.30

                  • 5.12

                  • T. Rowe Price New Horizons Fund

                  •  

                    5,618,600

                  • -0.11

                  • 3.27

                  • T. Rowe Price Small Cap Stock Fund

                  •  

                    4,611,700

                  • -0.49

                  • 2.68

                  • SPDR® S&P Pharmaceuticals ETF

                  •  

                    3,210,906

                  • 0.00

                  • 1.83

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,794,535

                  • 28.54

                  • 1.63

                  • iShares Russell 2000 (AU)

                  •  

                    2,584,188

                  • -1.81

                  • 1.47

                  • iShares Nasdaq Biotechnology

                  •  

                    2,511,300

                  • -0.24

                  • 1.43

                  • Oppenheimer Global Opportunities

                  •  

                    2,000,000

                  • 124.79

                  • 1.16

                  • Vanguard Extended Market Index Fund

                  •  

                    1,730,549

                  • 8.90

                  • 1.01

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • T. Rowe Price Associates, Inc.

                  •  

                    25,556,122

                  • -0.38%

                  • 14.87

                  • Baker Bros Advisors LLC

                  •  

                    18,558,487

                  • +220.52%

                  • 10.80

                  • Fidelity Management and Research Company

                  •  

                    13,304,800

                  • +9.50%

                  • 7.74

                  • Ingalls & Snyder LLC

                  •  

                    10,294,143

                  • -7.13%

                  • 5.99

                  • BlackRock Fund Advisors

                  •  

                    7,108,983

                  • -6.00%

                  • 4.14

                  • State Street Corp

                  •  

                    6,704,566

                  • -2.37%

                  • 3.90

                  • Millennium Management LLC

                  •  

                    4,868,557

                  • +104.94%

                  • 2.83

                  • Vanguard Group, Inc.

                  •  

                    4,582,561

                  • -1.84%

                  • 2.67

                  • TimesSquare Capital Management, LLC

                  •  

                    3,965,253

                  • -5.49%

                  • 2.31

                  • Wellington Management Company, LLP

                  •  

                    2,675,514

                  • +3.03%

                  • 1.56

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Growth

                  Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic ...moreproducts for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentratio...morens. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac®, Celexa®, Zoloft®, Paxil®, Elavil® and Pamelor® and others; Atypical antipsychotic agents, including Zyprexa®, Risperdal®, Seroquel, Abilify®, Geodon® and others; and Miscellaneous agents, including Symmetrel®, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.lessless

                  Key People

                  Keith A. Katkin

                  CEO/Director/President

                  Craig A. Wheeler

                  Chairman of the Board/Director

                  Christine G. Ocampo

                  CFO/Chief Accounting Officer/Secretary/Vice President, Divisional

                  Corinne H. Nevinny

                  Director

                  Mr. Dennis G. Podlesak

                  Director

                  • AVANIR Pharmaceuticals

                  • 20 Enterprise

                  • Aliso Viejo, CA 92656

                  • USA.Map

                  • Phone: +1 949 389-6700

                  • Fax: +1 949 389-6701

                  • avanir.com

                  Incorporated

                  1988

                  Employees

                  267

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: